May CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-α production in systemic sclerosis. June Blockade of the CX3CL1-CX3CR1 Pathway Inhibits the Progress of Skin Inflammation, Fibrosis, and Vascular Injury in an Experimental Mouse Model of Systemic Sclerosis July Microparticles in systemic sclerosis: Potential pro-inflammatory mediators and pulmonary hypertension biomarkers. August Activation of [...]
January Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimod READ MORE
READ MORE The Nrf2-Antioxidant Response Element SignallingPathway Controls Fibrosis and Autoimmunity in Scleroderma. Dysregulationsintheoxidant/antioxidantbalanceareknowntobemajorfactorsinthepathogenesisofsystemicsclerosis(SSc).NRF2actsasakeyplayerintheantioxidantdefensebycontrollingthetranscriptionofantioxidantandcytoprotectivegenes.Inthisarticle,theauthorsexploredtheinvolvementofadown-expressionofNRF2inthepathogenesisofSScandtherelevanceofaNRF2agonist,asapotenttherapeuticoptioninSSc.
READ MORE May 2018 Poly(ADP-ribose) polymerase-1 (PARP-1) regulates fibroblast activation in systemic sclerosis. The enzyme poly(ADP-ribose) polymerase-1 also called PARP-1, is a member of the PARP family, a group of 18 enzymes that transfer ADP-ribose groups onto various substrate proteins. This mechanism called PARylation, exerts profound regulatory effects on many physiological and pathological processes. Among [...]
January2018 The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis. In this article, the authors explored the role of the Jumonji domain-containing protein 3 (JMJD3) and the ubiquitously transcribed tetratricopeptide repeat on chromosome X (UTX), two highly specific histone–demethylases which could participate to the constitutively activated state of SSc fibroblasts. [...]